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Abstract
Background: The significant economic burden associated with acute coronary syndromes (ACS) provides a need
to evaluate both medical costs and productivity costs, according to evolving guideline-driven ACS treatment
strategies, medical management (MM), percutaneous coronary intervention (PCI), or coronary artery bypass graft
(CABG).
Methods: Commercially insured individuals, aged 18-64, with an emergency room (ER) visit or hospitalization
accompanied by an ACS diagnosis (index event) were identified from a large claims database between 01/2004
and 12/2005 with a 1-year follow-up period. Patients who had an ACS diagnosis in the 12 months prior to their
index event were excluded. Patients were divided into 3 groups according to treatment strategies during the index
event: MM, PCI, or CABG. A subset of patients was identified for the productivity cost analysis exploring short-term
disability and absenteeism costs. Multivariate generalized linear models were performed to examine the ACS costs
by 3 different treatment strategies.
Results: A total of 10,487 patients were identified for the medical cost analysis. The total 1-year medical costs
(index event costs plus the 1-year follow-up costs) were lowest for MM patients ($34,087), followed by PCI patients
($52,673) and CABG patients ($86,914). Of the 3,080 patients in the productivity costs analysis, 2,454 patients were
identified in the short-term disability cohort and 626 patients were identified in the absenteeism cohort. Both the
estimated mean total 1-year short-term disability and absenteeism costs were highest for CABG patients ($17,335,
$14,960, respectively) compared to MM patients ($6,048, $9,826, respectively) and PCI patients ($9,221, $9,460,
respectively).
Conclusions: Both total 1-year medical costs and 1-year productivity costs are substantial for working-aged
individuals with ACS. These costs differ according to the type of treatment strategy, with CABG having higher costs
compared to either PCI or MM.
Background
Acute coronary syndromes (ACS), including unstable
angina (UA), non-ST-segment elevation myocardial
infarction (NSTEMI), and ST-segment elevation myo-
cardial infarction (STEMI), are common and costly. In
2006 alone, it was estimated that 733,000 hospital dis-
charges were due to ACS, increasing to 1,365,000 when
adding secondary discharges [1]. The morbidity and
mortality associated with ACS are substantial, as half of
all deaths due to cardiovascular disease are attributed to
ACS [2]. Further, the economic impact of ACS has been
estimated as high as $150 billion annually [2]. With the
large number of patients impacted by ACS, it becomes
increasingly important to examine the economic burden
of this illness in terms of both medical and productivity
costs.
The substantial costs associated with ACS include
treatment related medical costs, as well as costs due to
loss of productivity [3]. Previous studies evaluating med-
ical costs have shown total first-year treatment cost esti-
mates to be $22,528 to $32,345, with the majority of
these costs due to hospitalizations [4-6]. The American
Heart Association estimates that loss of productivity for
coronary heart disease will account for nearly $81.1 bil-
lion in 2009, and there are limited data available on the
productivity costs of ACS specifically [1]. With prior
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with ACS, there is an unmet need for research exploring
the impact of productivity costs.
Analyzing ACS costs by different treatment strategies
should be of special interest to healthcare professionals
as different treatment strategies are important drivers of
ACS costs and may have different implications on
healthcare resource utilization and productivity loss of
patients. Depending on the different manifestations of
ACS, UA/NSTEMI versus STEMI, the current 2007
American College of Cardiology/American Heart Asso-
ciation (ACC/AHA) guidelines allow conservative non-
interventional medical management (MM) and/or
invasive interventional management by percutaneous
coronary intervention (PCI) or coronary artery bypass
graft (CABG) [7,8]. There are limited data available on
the effects of different treatment strategies on the costs
of ACS.
Over the years, the ACC/AHA guidelines have been
updated to reflect new data and clinical trial results.
Previous studies investigating the cost of illness for
ACS, however, have focused on data from the late 1990s
or early 2000s, prior to the results of the Clopidogrel in
Unstable angina to prevent Recurrent Events (CURE)
trial for clopidogrel [9], as well as several versions of the
ACC/AHA guidelines. With the implementation of the
updated ACC/AHA guidelines and the increased use of
clopidogrel, the outcomes and costs associated with
ACS may have changed. The goals of this study were to
estimate both 1-year medical costs and productivity
(short-term disability and absenteeism) costs by using
more recent data, and to assess the effects of treatment
strategies (MM, PCI, and CABG) during the index ACS
event on costs.
Methods
Data Source
These retrospective claims database analyses were per-
formed using two of the Thomson Reuters MarketScan
®
Research Databases. For the medical cost analyses, the
MarketScan Commercial Claims and Encounters
(CCAE) database was used. The CCAE database cap-
tures individual-level clinical utilization, costs, and
enrollment across inpatient, outpatient and prescription
drug categories from a selection of large United States
(US) employers with contributing health plans. The
MarketScan Health and Productivity Management
(HPM) database was used for the productivity cost ana-
lyses. The HPM database is a subset of the CCAE data-
base and contains information on short-term disability,
absence, and workers’ compensation experience that is
linkable to the medical, pharmacy, and enrollment data
in MarketScan databases.
Study Design
Medical claims data were extracted from January 2003
to December 2006 for individuals, aged 18-64, that were
seen in an emergency room (ER) or hospitalized
between January 2004 and December 2005 with a diag-
nosis of ACS, based on ICD-9-CM codes 410.xx and
411.1. The first ACS-related ER visit or hospitalization
w a sc o n s i d e r e da st h e“index event.” Patients who had
an ACS diagnosis one year prior to the index event
were excluded from the study. Patients were required to
have a minimum 12 months of continuous insurance
eligibility prior to and post the index event. Patients
were categorized into three groups according to their
ACS treatment strategy during the index event: MM,
PCI, or CABG. For the subset productivity cost analyses,
patients were required to have had a minimum of
12-months eligibility for incurring short-term disability
and absence in the HPM database. Data for these indivi-
duals were linked to their employers’ short-term disability
and absenteeism records via unique encrypted personal
identification numbers provided by the employers.
Data Analyses
All statistical analyses were performed with Stata 9 soft-
ware (College Station, Texas, USA) and an ap r i o r i
p-value of 0.05 was considered statistically significant.
Descriptive analyses according to MM, PCI, and CABG
were performed on patient demographic and clinical
characteristics using chi-square tests for categorical vari-
ables and t tests for continuous variables. The demo-
graphic characteristics included age, gender, insurance
plan type (see Appendix for description), and geographic
region. The clinical characteristics included comorbid-
ities, the Charlson comorbidity score [10], primary
admission diagnosis, length of stay, and discharge mor-
tality rate.
Medical costs were categorized into costs incurred
during the index event and costs incurred during the
1-year follow-up period for MM, PCI, and CABG
patients. For the 1-year follow-up costs, costs were
further divided into inpatient, outpatient, and pharmacy
costs. All costs were reported in 2005 US dollars. For
the productivity cost analyses, short-term disability and
absenteeism costs incurred during the 1-year follow-up
period were estimated for the MM, PCI, and CABG
groups. These productivity costs were further divided
into two categories for each group: the costs incurred
within the first 30 days of the index event and the costs
incurred from day 31 through one year. The hourly
v a l u eo f$ 4 2 . 6 7o fp r o d u c t i v ity losses was estimated
based on the average hourly wage and benefits rate
reported in the 1999 Medstat Benchmark Survey of
Hourly Compensation and inflated using the 2005
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Private Industry [11]. Differences in unadjusted medical
and productivity costs were descriptively compared
across MM, PCI, and CABG groups by using nonpara-
metric Wilcoxon rank sum tests. To account for the
non-negativity and skewed distribution of costs and
short-term disability and absenteeism days and to avoid
heteroscedasticity in simple least-squares models, gener-
alized linear models (GLM) with log link function and
gamma distribution were used [12-15]. Specifically, mul-
tivariate GLM were performed to study the effects of
treatment strategies on the total 1-year medical costs
and productivity costs, while controlling for patient
characteristics including age, gender, insurance plan
type, Charlson comorbidity score, primary admission
diagnosis, and treatment strategy. The cost ratio (the
exponential of the beta coefficient from the GLM esti-
mation) was presented to show the relative increase in
mean costs by increasing covariates by 1 unit [15]. Sta-
tistical bootstrapping was used to obtain 95% confidence
intervals.
Results
Patient Characteristics
A total of 10,487 ACS patients was identified and
divided into three mutually exclusive groups according
to treatment strategy during their index event: MM (n =
4,894), PCI (n = 4,729), and CABG (n = 864). Patient
demographic and clinical characteristics for the total
population are displayed in Table 1. The average ages
for MM, PCI, and CABG patients were 54.3, 54.8, and
56.5, respectively. Overall, patients in the MM group
were significantly (p < 0.05) more likely to be female, be
younger, and have a higher mean Charlson comorbidity
score compared to the PCI and CABG groups. In addi-
tion, patients in the PCI and CABG groups had signifi-
cantly (p < 0.05) longer mean lengths of stay compared
to MM patients during the index event: 3.14 days,
8.65 days, and 1.63 days, respectively.
For the productivity cost analysis, 3,080 patients had
available data for analysis with 2,454 patients in the
short-term disability cohort (MM: n = 1,169, PCI: n =
1,034, and CABG: n = 251) and 626 patients in the
absenteeism cohort (MM: n = 337, PCI: n = 230, and
C A B G :n=5 9 ) .I nb o t hc o h o r t s ,M Mp a t i e n t sw e r e
more likely to be female, be younger, and have a higher
mean Charlson comorbidity score compared to PCI and
CABG patients.
Medical Costs
Table 2 presents the total medical costs (index event
costs plus 1-year follow-up costs) for the MM, PCI, and
CABG groups. Index event costs were lowest for MM
patients ($8,905), followed by PCI patients ($31,379) and
CABG patients ($63,909), respectively (p < 0.05). Index
event costs for the interventional treatments accounted
for 59.6% (PCI) and 73.5% (CABG) of the total medical
costs for those groups, and 26.1% of the total medical
costs for the MM group. Of the total 1-year follow-up
costs, rehospitalization costs accounted for 45.3% for the
MM group, 41.2% for the PCI group, and 43.5% for the
CABG group, with ACS-related rehospitalization costs
accounting for 18.5%, 17.4%, and 15.2%, respectively.
ACS-related prescription drug costs accounted for 4.9%,
10.9% and 6.6% of the 1-year follow-up costs for MM,
PCI, and CABG patients, respectively. The total costs
obtained by adding the index event costs to the 1-year
follow-up costs were lowest for MM patients ($34,087),
followed by PCI patients ($52,673) and CABG patients
($86,914), respectively (p < 0.05).
Table 3 displays the results from the multivariate
regression analysis for the mean total 1-year medical
costs. Female gender was significantly (p < 0.05) asso-
ciated with lower 1-year costs. All other parameters
were significantly (p < 0.05) associated with higher
1-year costs: increasing age, insurance plan type other
than a health maintenance organization (HMO), higher
Charlson comorbidity scores, myocardial infarction (MI)
as the primary admission diagnosis, and interventional
treatment strategies (PCI and CABG). Controlling for
patient characteristics, the estimated mean total 1-year
medical costs were calculated to be $39,017 (95% CI:
$36,332-$41,702) for MM patients, $58,313 (95%
CI: $54,972-$61,653) for PCI patients, and $91,977 (95%
CI: $85,044-$98,910) for CABG patients.
Productivity Costs
For the 1-year productivity costs, Table 4 shows that
patients in the CABG group had significantly (p < 0.05)
higher 1-year short-term disability costs ($17,335) and
absenteeism costs ($14,960) compared to MM patients
(short-term disability costs: $6,048 and absenteeism
costs: $9,826) and PCI patients (short-term disability
costs: $9,221 and absenteeism costs: $9,460). The major-
ity of the short-term disability costs occurred within the
first 30 days of the index event for all three groups. In
contrast, the majority of the absenteeism costs for all
three groups occurred after 30 days from the index
event, between day 31 and the end of the 1-year follow-
up period.
Tables 5 and 6 present the results of the multivariate
regression analysis for the mean total 1-year short-term
disability costs and mean total 1-year absenteeism costs,
respectively. For the short-term disability cohort, female
gender was significantly (p < 0.05) associated with lower
costs and MI as the primary admission diagnosis and
interventional treatment strategies (PCI and CABG)
were significantly (p < 0.05) associated with higher
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Variables MM
n = 4,894
PCI
n = 4,729
CABG
n = 864
p-value*
Age, mean (SD) 54.3 (7.3) 54.8 (6.6) 56.5 (5.7) a,b,c
Age group (%)
18-34 years 1.6 0.7 0.1 a,b,c
35-44 years 9.1 7.1 3.8
45-54 years 32.3 34.0 28.0
55-64 years 57.0 58.2 68.1
Gender (%)
Female 42.2 21.0 22.1 b,c
Plan Type (%)
Comprehensive 19.1 17.0 19.4 b,c
HMO 21.0 16.0 14.0
PPO 46.9 52.6 52.7
POS 12.5 13.7 13.2
Unknown 0.5 0.7 0.7
Region (%)
Northeast 8.2 7.0 5.7 n.s.
Northcentral 35.6 36.2 35.9
South 40.0 41.2 44.7
West 15.9 15.2 13.4
Unknown 0.4 0.3 0.3
Comorbidities (%)
Diabetes without chronic complications 25.0 18.2 24.9 a,b
Diabetes with chronic complications 3.1 1.4 2.1 b
Congestive heart failure 7.5 2.0 2.4 b,c
Cerebrovascular disease 7.0 3.2 4.4 b,c
Peripheral vascular disease 3.4 1.8 1.9 b,c
Renal disease 3.4 1.3 1.6 b,c
Rheumatologic disease 2.1 1.3 1.7 b
Peptic ulcer disease 0.8 0.5 0.5 n.s.
Chronic pulmonary disease 14.2 10.2 8.8 b,c
Any malignancy 4.4 3.4 3.7 b
Metastatic solid tumor 0.6 0.3 0.1 b
Mild liver disease 0.6 0.2 0.2 b
Moderate or severe liver disease 0.2 0.06 0.1 b
AIDS 0.2 0.2 0 n.s.
Dementia 0.2 0.1 0.1 n.s.
Hemiplegia or paraplegia 0.2 0.02 0.1 b
Mean (SD) Charlson Comorbidity Score 0.75 (1.16) 0.48 (0.89) 0.56 (0.88) a,b,c
MI listed as the primary diagnosis (%) 34.2 69.9 57.9 a,b,c
Length of stay (days)
Mean (SD) 1.63 (3.01) 3.14 (2.41) 8.65 (5.15) a,b,c
Median 1 3 8
75th percentile 2 4 10
Mortality rate at hospital discharge 0.2 0.1 0.2 n.s.
*n.s. = not significant; a = p < 0.05 CABG vs. PCI; b = p < 0.05 MM vs. PCI; c = p < 0.05 MM vs. CABG.
CABG = coronary artery bypass graft; HMO = health maintenance organization; MI = myocardial infarction; MM = medical management; PCI = percutaneous
coronary intervention; POS = point of service; PPO = preferred provider organization; SD = standard deviation.
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insurance plan type other than an HMO were signifi-
cantly (p < 0.05) associated with lower costs, while age
(45-54 vs. ≤44 years) and CABG (vs. MM) were both
significantly (p < 0.05) associated with higher costs.
Controlling for patient characteristics, the estimated
mean total 1-year short-term disability costs were
$5,937 (95% CI: $4,293-$7,582) for MM patients, $9,400
(95% CI: $7,084-$11,718) for PCI patients, and $18,051
(95% CI: $13,435-$22,668) for CABG patients. The esti-
mated mean total 1-year absenteeism costs were $9,733
(95% CI: $7,501-$11,966) for MM patients, $9,785 (95%
CI: $7,731-$12,138) for PCI patients, and $13,958 (95%
CI: $9,649-$18,266) for CABG patients.
Discussion
This study contributes to the existing medical literature
by utilizing more recent data than previously reported
ACS cost studies [4-6] to examine both the medical and
productivity costs associated with patients treated with
MM, PCI or CABG during their ACS index events. This
study demonstrated the substantial economic burden
associated with ACS in terms of both medical costs and
productivity costs, and the costs differed according to
treatment strategy (MM, PCI, or CABG) employed dur-
ing the index event.
The total 1-year medical costs for patients treated
conservatively by MM were $34,087, significantly lower
compared to patients treated interventionally by PCI
($52,673) or CABG ($86,914). When controlling for
patient characteristics, a similar trend was found: the
total adjusted 1-year medical costs were $39,017 for
MM patients, $58,313 for PCI patients, and $91,977 for
CABG patients. All three treatment strategies had higher
total 1-year medical costs compared to previous studies
resulting from earlier data that reported estimates of
Table 2 Mean total medical costs by ACS index event treatment strategy
Variables MM
n = 4,894
PCI
n = 4,729
CABG
n = 864
p-value*
Index Event Costs, $ (SD) 8,905 (14,832) 31,379 (22,569) 63,909 (43,620) a,b,c
1-Year Follow-Up Costs, $ (SD)
Inpatient 11,397 (35,335) 8,781 (23,877) 10,017 (35,177) b,c
Outpatient 10,583 (20,956) 8,883 (20,693) 9,980 (21,077) a,b
Pharmacy 3,202 (4,031) 3,630 (3,128) 3,008 (3,058) a,b,c
Total 1-Year Follow-Up Costs 25,182 (45,625) 21,294 (35,327) 23,005 (46,999) n.s.
Total Medical Costs, $ (SD) 34,087 (49,958) 52,673 (44,957) 86,914 (69,836) a,b,c
*n.s. = not significant; a = p < 0.05 CABG vs. PCI; b = p < 0.05 MM vs. PCI; c = p < 0.05 MM vs. CABG.
CABG = coronary artery bypass graft; MM = medical management; PCI = percutaneous coronary intervention; SD = standard deviation.
Table 3 Results from multivariate regression for mean total 1-year medical costs
Variables Cost Ratio 95% CI p-value
Age Groups
Age 45-54 (vs. ≤44 years) 1.109 1.029 - 1.195 0.006
Age 55+ (vs. ≤44 years) 1.187 1.109 - 1.269 < 0.0001
Gender
Female 0.906 0.869 - 0.945 < 0.0001
Plan Type
Comprehensive (vs. HMO) 1.084 1.018 - 1.155 0.01
PPO (vs. HMO) 1.246 1.179 - 1.318 < 0.0001
POS (vs. HMO) 1.116 1.040 - 1.198 0.002
Charlson score = 1 (vs. Charlson score = 0) 1.133 1.092 - 1.176 < 0.0001
Charlson score > 1 (vs. Charlson score = 0) 1.311 1.237 - 1.389 < 0.0001
MI listed as the primary diagnosis 1.351 1.302 - 1.402 < 0.0001
CABG (vs. MM) 2.693 2.519 - 2.879 < 0.0001
PCI (vs. MM) 1.595 1.521 - 1.674 < 0.0001
Prior 1-year health care costs 1.000 1.000 - 1.000 < 0.0001
CABG = coronary artery bypass graft; CI = confidence interval; HMO = health maintenance organization; MI = myocardial infarction; MM = medical management;
PCI = percutaneous coronary intervention; POS = point of service; PPO = preferred provider organization.
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estimates observed in this study compared to the these
earlier studies may be due to the general trend of
increasing healthcare costs, as well as the use of newer
data reflecting changes in treatment strategies along
with advances in cardiovascular technology and updated
ACC/AHA guidelines. Mortality and outcomes of ACS
patients have improved over the last 2 decades due to
innovations in pharmacological and interventional treat-
ments in patients, as well as quality improvement initia-
tives “to move from dealing with individual clinical
errors to helping providers to improve the mainstream
of care,” while focusing on targeted aspects of care
including time to reperfusion for STEMI patients and
the use of evidence-based therapies during hospitaliza-
tion, discharge, and postdischarge care [16-18]. Based
on a risk stratification approach, the use of PCI or
CABG is recommended for high-risk patients presenting
with UA/NSTEMI, with a more conservative strategy of
MM for low-risk UA/NSTEMI patients [2,7]. Patients
that present with STEMI are recommended to receive
reperfusion therapy with primary PCI within 90 minutes
of initial medical contact [2,8]. While the rates of CABG
have remained relatively stable over the years, the rates
of PCI have increased, with an estimated 1,313,000 inpa-
tient PCI procedures performed in 2006 [1,2,19].
These results show that PCI and CABG patients had
higher total medical costs when compared to MM
patients. For both interventional treatments strategies,
the majority of the costs occurred during the index
event: 59.6% for PCI patients and 73.5% for CABG
patients, compared to 26.1% for MM patients. This find-
ing is consistent with earlier studies showing the major-
ity of medical costs resulting from the index event [4-6].
During the 1-year follow-up period, the medical costs
for MM patients ($25,182), PCI patients ($21,294), and
CABG patients ($23,005) were similar. During the
1-year follow-up period, rehospitalizations accounted for
Table 4 Mean 1-year productivity costs by ACS index event treatment strategy
Variables MM PCI CABG p-value*
Short-Term Disability Costs, $ (SD) n = 1,169 n = 1,034 n = 251
≤30 days from index hospitalization 3,578 (10,131) 6,923 (13,510) 15,995 (19,100) a,b,c
> 30 days - 1 year from index hospitalization 2,470 (8,455) 2,298 (8,006) 1,340 (6,339) a,c
Total Short-Term Disability Costs 6,048 (13,446) 9,221 (15,631) 17,335 (19,987) a,b,c
Absenteeism Costs, $ (SD) n = 337 n = 230 n = 59
≤30 days from index hospitalization 1,505 (2,038) 1,767 (2,257) 2,627 (2,995) n.s.
> 30 days - 1 year from index hospitalization 8,320 (8,379) 7,692 (7,581) 12,332 (12,281) a,c
Total Absenteeism Costs 9,826 (9,808) 9,460 (9,067) 14,960 (14,623) a,c
*n.s. = not significant; a = p < 0.05 CABG vs. PCI; b = p < 0.05 MM vs. PCI; c = p < 0.05 MM vs. CABG.
CABG = coronary artery bypass graft; MM = medical management; PCI = percutaneous coronary intervention; SD = standard deviation.
Table 5 Results from multivariate regression for mean total 1-year short-term disability costs
Variables Cost Ratio 95% CI p-value
Age Groups
Age 45-54 (vs. ≤44 years) 1.065 0.816 - 1.389 0.645
Age 55+ (vs. ≤44 years) 0.991 0.771 - 1.274 0.942
Gender
Female 0.675 0.534 - 0.855 0.001
Plan Type
Comprehensive (vs. HMO) 0.917 0.655 - 1.284 0.615
PPO (vs. HMO) 1.173 0.861 - 1.598 0.312
POS (vs. HMO) 0.655 0.424 - 1.013 0.057
Charlson score = 1 (vs. Charlson score = 0) 1.186 0.977 - 1.441 0.085
Charlson score > 1 (vs. Charlson score = 0) 1.146 0.906 - 1.450 0.256
MI listed as the primary diagnosis 1.542 1.329 - 1.788 < 0.001
CABG (vs. MM) 2.677 2.230 - 3.214 < 0.001
PCI (vs. MM) 1.304 1.092 - 1.558 0.003
CABG = coronary artery bypass graft; CI = confidence interval; HMO = health maintenance organization; MI = myocardial infarction; MM = medical management;
PCI = percutaneous coronary intervention; POS = point of service; PPO = preferred provider organization.
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41.2% (PCI group), and 43.5% (CABG). The overall
pharmacy costs during the 1-year follow-up period con-
tributed the lowest percentages of the total costs for all
three treatment strategies.
T oo u rk n o w l e d g e ,t h i si st h ef i r s ts t u d ye x a m i n i n g
productivity costs associated with ACS, and the results
show the substantial impact on productivity costs. In
this study, the productivity costs include short-term dis-
ability and absenteeism costs, which are true costs to
employers-as employers have to either spend extra
resources, such as overstaffing or hiring replacement, to
compensate for work normally performed by absent
employees or to experience the productivity loss with
fewer goods and services provided, lower revenues, and
lower profits. In both the short-term disability and
absenteeism cohorts, CABG patients had the highest
total productivity costs compared to both MM patients
and PCI patients. For short-term disability costs, the
CABG group had the highest costs within the first
30 days, but had the lowest costs after the first 30 days
compared to the MM and PCI groups. In the absentee-
ism cohort, there was no difference in costs between the
three treatment groups during the first 30 days. How-
ever, after the first 30 days, CABG patients had signifi-
cantly higher costs. For all three treatment groups, the
majority of the short-term disability costs occurred
within the first 30 days of the index event, and the
majority of the absenteeism costs occurred after 30 days
from the index event.
The treatment of ACS includes an inpatient diagnosis
and treatment strategy during the index event, followed
by long-term treatment of the underlying coronary heart
disease condition. Therefore, it is important to under-
stand the costs associated with different treatment stra-
tegies, not only during the index event, but also over
time. This study was unique in dividing the costs
according to the treatment strategy, MM, PCI, or
CABG, employed during the initial ACS hospitalization.
The results showed that for PCI and CABG patients, the
majority of the costs were incurred during the index
event. Costs across all three groups were similar during
the 1-year follow-up period. A better understanding of
the costs associated with different treatment strategies
for ACS patients will help health care practitioners and
policy makers in their decision-making process.
Certain limitations must be considered when inter-
preting these results. Retrospective data analyses were
performed; therefore, miscoding of medical claims and
missing data, which could not be verified through medi-
cal chart reviews, are both possible. In addition, as
patients in the study were required to have a minimum
12 months of continuous insurance eligibility after the
index date, the results applied only to patients who sur-
vived and who did not switch or lose their jobs at least
1 year following their initial hospitalization for ACS.
Using an alternative cohort definition, including those
patients who lost follow-up during the 12 months after
their index events, might have opposite effects on the
cost estimation. First, incorporating those who died over
the course of 1 year might increase the healthcare costs
estimation due to higher end-of-life healthcare. On the
other hand, incorporating patients, who experienced job
changes or job loss during the one year period after
their ACS index events, might lead to lower cost estima-
tion due to loss of insurance eligibility. Mortality status
Table 6 Results from multivariate regression for mean total 1-year absenteeism costs
Variables Cost Ratio 95% CI p-value
Age Groups
Age 45-54 (vs. ≤44 years) 1.176 1.005 - 1.376 0.04
Age 55+ (vs. ≤44 years) 0.865 0.698 - 1.072 0.18
Gender
Female 0.789 0.649 - 0.959 0.02
Plan Type
Comprehensive (vs. HMO) 0.318 0.195 - 0.517 < 0.0001
PPO (vs. HMO) 0.725 0.571 - 0.920 0.008
POS (vs. HMO) 0.509 0.410 - 0.632 < 0.0001
Charlson score = 1 (vs. Charlson score = 0) 1.145 0.947 - 1.384 0.945
Charlson score > 1 (vs. Charlson score = 0) 0.993 0.824 - 1.198 0.164
MI listed as the primary diagnosis 1.047 0.863 - 1.271 0.639
CABG (vs. MM) 1.415 1.083 - 1.848 0.011
PCI (vs. MM) 0.965 0.837 - 1.113 0.624
CABG = coronary artery bypass graft; CI = confidence interval; HMO = health maintenance organization; MI = myocardial infarction; MM = medical management;
PCI = percutaneous coronary intervention; POS = point of service; PPO = preferred provider organization.
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Page 7 of 9is unknown in the database, unless a patient died in the
hospital and the loss of follow-up reason is unclear due
to death, job changes, or job loss, etc. As a result, it is
unclear how this would impact the cost estimation;
therefore, a clear defined cohort was chosen for the
study to understand the 1-year medical and productivity
costs of ACS to employers.
The productivity cost analyses were limited to short-
term disability and absenteeism, and did not include
presenteeism (productivity loss due to intermittent
reduced output, while at work) or long-term disability.
T h er e s u l t sf r o mt h i ss t u d ym a yn o tb eg e n e r a l i z a b l et o
populations other than working-age populations with
employer-sponsored private health insurance plans, such
as retired patients or Medicaid beneficiaries.
Conclusions
In conclusion, this study examined the total 1-year med-
ical and productivity costs associated with short-term
disability and absenteeism according to ACS index event
treatment strategies, MM, PCI, or CABG. Both total
1-year medical and productivity costs were substantial
for working-age individuals with ACS, and these costs
differed according to the type of treatment strategy with
CABG patients having the highest 1-year medical and
productivity costs compared to PCI and MM patients.
Treatment options that reduce resource utilization and
improve productivity may potentially lower the costs of
care for ACS.
MarketScan is a registered trademark of Thomson
Reuters (Healthcare) Inc.
Appendix
Insurance plan type description:
A variety of insurance plan types was available in the
dataset used in this analysis, including fee-for-service
(FFS), fully capitated, and partially capitated health
plans, including preferred provider organizations (PPO),
point of service (POS) plans, comprehensive plans, and
health maintenance organizations (HMO). Specifically,
in comprehensive plans there is no incentive for the
patient to use a particular list of providers. Coverage is
handled by one or two policies, with a deductible and
coinsurance. Patients who have an HMO plan must
choose from a particular list of providers for all non-
emergency care. Referral from the patient care provider
(PCP) is required for treatment by specialists. All ser-
vices are paid for by the plan on a capitated basis. In
POS plans, patients are offered financial incentives,
through a lower copay or deductible, to use a particular
list of providers. Referral from the PCP is required for
treatment by specialists. Either no or some services are
capitated and patients may seek treatment outside the
network; however, this option usually involves a severe
financial penalty. Patients who have a PPO plan have
financial incentives, often through a lower copay or
deductible, to use a particular list of providers. No PCP
is required, nor are referrals necessary. No services are
capitated. Patients may seek treatment outside the net-
work, but this option is usually at a higher cost to the
patient. The financial incentives may be offered only
through discounted rates in-network.
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